September 4, 2020 -- The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.
The drug candidates include novel bispecific antibodies and engineered cytokines with a heterodimer Fc domain, which enables rapid design, simplified development, and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in phase I clinical studies conducted by Xencor and its partners:
Xencor has committed to funding and supporting these studies over an initial five-year term.